Streetbeat News

Products Services

CEVA

Ceva has announced the introduction of Ceva-NeuPro-Nano NPUs, a new line of neural processing units designed for AI and machine learning applications. This product launch aims to enhance the company's position in the AI and machine learning market.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:05 am

RANI

Rani Therapeutics has entered into a definitive agreement with ProGen for the co-development and commercialization of RT-114, an oral Ranipill capsule containing ProGen's PG-102, a GLP-1/GLP-2 dual agonist, for obesity. The agreement includes a 50/50 cost and revenue share arrangement, with Rani leading development in the US, Europe, Canada, and Australia, and ProGen leading in the rest of the world. Phase 1 program is expected to initiate in 2025.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:05 am

HRMY

Harmony Biosciences has received FDA approval for a supplemental new drug application for WAKIX, which is expected to enhance its market position and potentially increase revenues.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:05 am

CANF

Can-Fite BioPharma Ltd. (NYSE:CANF) announced breakthrough findings on Namodenoson's dual anti-cancer and liver protective effects, mediated by the signalling protein adiponectin. These findings will be presented at the IDDST-2024 conference in Shanghai. Namodenoson is currently in Phase III and Phase IIb clinical trials for advanced liver cancer and MASH, respectively.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:04 am

ALTR

HPQ

Altair has signed a collaboration agreement with HP to enhance its Material Data Center with proprietary material information from HP. This will benefit designers, engineers, and scientists using Altair's tools.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:03 am

AXGN

Axogen, Inc. (NASDAQ:AXGN) has launched a new product, Avive+ Soft Tissue Matrix, designed to aid in nerve healing. This product is a resorbable, multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during the critical phase of peripheral nerve healing. The product complies with FDA regulations and aims to address a significant need in the $800 million nerve protection market.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:03 am

ALNY

Alnylam Pharmaceuticals announced positive topline results from its HELIOS-B Phase 3 study of Vutrisiran. The study achieved statistical significance on both primary and all secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:02 am

GOEV

Canoo Inc. (NASDAQ:GOEV) has enhanced its production capabilities by acquiring advanced manufacturing assets from Arrival Automotive UK Limited. These assets will improve production efficiency and scalability at Canoo's Oklahoma City facility, which manufactures electric cargo vehicles.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:02 am

BNTX

BioNTech and Duality Biologics announced that the FDA has granted Fast Track Designation for BNT324/DB-1311 for advanced or metastatic castration-resistant prostate cancer patients who have progressed on or after standard systemic regimens.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:02 am

BG

BP

CSAN

SHEL

BP p.l.c. (NYSE:BP) plans to expand its biofuel operations in Brazil after acquiring Bunge Global SA's (NYSE:BG) 50% stake in their joint venture, BP Bunge Bioenergia S.A., for $1.4 billion. This move will consolidate 100% of the venture's financial results. BP aims to explore new bioenergy platforms, including second-generation ethanol and sustainable aviation fuel. This strategy mirrors Shell plc's (NYSE:SHEL) partnership with Cosan S.A. (NYSE:CSAN) in Raizen SA, which focuses on second-generation ethanol.

Portfolio Pulse from Lekha Gupta

June 24, 2024 | 10:58 am